Histone deacetylases (HDACs) are emerging as exciting new targets for drug development, particularly for cancer and metabolic diseases. Because they exert control over gene transcription and ...
Though there are four histone deacetylase (HDAC) inhibitors that are FDA approved to treat some forms of lymphoma, there’s less evidence for their efficacy in solid tumors. Now, new findings in mice ...
As gene regulation changes in Alzheimer’s disease, scientists believe that histone deacetylases (HDACs) go into overdrive, shutting down transcription of certain genes. Consequently, several research ...
The mining pool of Hyundai-related IoT blockchain platform HDAC has been hacked, forcing the company to temporarily halt withdrawals. The mining pool of HDAC, a Korean blockchain-based IoT platform ...
DelveInsight’s 'HDAC Inhibitor Pipeline Insight 2023' report provides comprehensive global coverage of pipeline HDAC inhibitors in various stages of clinical development, major pharmaceutical ...
Most pancreatic tumors are surrounded by a thick, nearly impenetrable wall of fibrosis— scar tissue—that makes it hard for drugs to access and destroy the cancer cells. Researchers at the Salk ...
Pancreatic cancer is one of the deadliest cancers - only about one in eight patients survives five years after diagnosis. Those dismal statistics are in part due to the thick, nearly impenetrable wall ...
Histone deacetylase (HDAC) antibodies are used to study the process of histone deacetylation, an essential activity that happens within human cells. Numerous assays currently exist that rely on the ...
The approval by the US Food and Drug Administration (FDA) of the first histone deacetylase (HDAC) inhibitor in October went largely unnoticed. “A quiet event,” Daniel Von Hoff, head of translational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback